Evidence map›Paper›PMID 35202067›Full record

ArticlePharmacy (Basel, Switzerland)2022

Need for Expansion of Pharmacy Education Globally for the Growing Field of Nanomedicine.

Amy E Barton, Gerrit Borchard, Matthias G Wacker, Giorgia Pastorin, Imran Y Saleem, Shaqil Chaudary, Tamer Elbayoumi, Zhigang Zhao, Beat Flühmann

Abstract read
In one paragraph

Article in Pharmacy (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amy E BartonVifor Pharma Group, Vifor Pharma Management Ltd., Flughofstrasse 61, 8152 Glattbrugg, Switzerland.
Gerrit BorchardSection of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva,1, Rue Michel Servet, 1211 Geneva, Switzerland.ORCID 0000-0001-6268-2586
Matthias G WackerDepartment of Pharmacy, Faculty of Science, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore.ORCID 0000-0002-2789-6463
Giorgia PastorinDepartment of Pharmacy, Faculty of Science, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore.ORCID 0000-0002-2568-0626
Imran Y SaleemSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK.ORCID 0000-0003-2382-6668
Shaqil ChaudarySchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK.
Tamer ElbayoumiDepartment of Pharmaceutical Sciences & Nanomedicine Center of Excellence, College of Pharmacy Glendale Campus, Midwestern University, 19555 N. 59th Avenue, Glendale, AZ 85308, USA.ORCID 0000-0001-9173-2167
Zhigang ZhaoDepartment of Clinical Pharmacy, School of Pharmacy, Capital Medical University, No.10, Xitoutiao, You'anmen Wai, Fengtai District, Beijing 100069, China.
Beat FlühmannVifor Pharma Group, Vifor Pharma Management Ltd., Flughofstrasse 61, 8152 Glattbrugg, Switzerland.ORCID 0000-0002-3077-298X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emerging landscape of nanomedicine includes a wide variety of active pharmaceutical ingredients and drug formulations. Their design provides nanomedicines with unique features leading to improved pharmacokinetics and pharmacodynamics. They are manufactured using conventional or biotechnological manufacturing processes. Their physical characteristics are vastly different from traditional small-molecule drugs. Pharmacists are important members of the multi-disciplinary team of scientists involved in their development and clinical application. Consequently, their training should lead to an understanding of the complexities associated with the production and evaluation of nanomedicines. Therefore, student pharmacists, post-doctoral researchers, and trainees should be given more exposure to this rapidly evolving class of therapeutics. This commentary will provide an overview of nanomedicine education within the selection of pharmacy programs globally, discuss the current regulatory challenges, and describe different approaches to incorporate nanomedicine science in pharmacy programs around the world.

Indexed as

liposomesnanomedicinenanoparticlespharmacistpharmacy

Identifiers

PMID35202067
PMCPMC8878512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.